BMC Public Health by Stockbridge, Erica L. et al.
RESEARCH ARTICLE Open Access
Predictors of latent tuberculosis infection
treatment completion in the US private
sector: an analysis of administrative claims
data
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Abstract
Background: Factors that affect latent tuberculosis infection (LTBI) treatment completion in the US have not been
well studied beyond public health settings. This gap was highlighted by recent health insurance-related regulatory
changes that are likely to increase LTBI treatment by private sector healthcare providers. We analyzed LTBI
treatment completion in the private healthcare setting to facilitate planning around this important opportunity for
tuberculosis (TB) control in the US.
Methods: We analyzed a national sample of commercial insurance medical and pharmacy claims data for people
ages 0 to 64 years who initiated daily dose isoniazid treatment between July 2011 and March 2014 and who had
complete data. All individuals resided in the US. Factors associated with treatment completion were examined
using multivariable generalized ordered logit models and bivariate Kruskal-Wallis tests or Spearman correlations.
Results: We identified 1072 individuals with complete data who initiated isoniazid LTBI treatment. Treatment
completion was significantly associated with less restrictive health insurance, age < 15 years, patient location, use of
interferon-gamma release assays, non-poverty, HIV diagnosis, immunosuppressive drug therapy, and higher
cumulative counts of clinical risk factors.
Conclusions: Private sector healthcare claims data provide insights into LTBI treatment completion patterns and
patient/provider behaviors. Such information is critical to understanding the opportunities and limitations of private
healthcare in the US to support treatment completion as this sector’s role in protecting against and eliminating TB
grows.
Keywords: Latent tuberculosis infection, LTBI, Treatment completion, Claims data, Administrative data, Isoniazid,
Epidemiology, Health service delivery, Public health practice, Medication adherence
Background
Up to 13 million people in the US have latent tuberculosis
infection (LTBI) [1, 2]. These people are infected with
Mycobacterium tuberculosis yet do not have active tubercu-
losis (TB) disease; they are asymptomatic and cannot trans-
mit TB. Without treatment 5–10% of people with LTBI will
develop TB over time, with higher progression risk among
immunocompromised persons [3]. Although LTBI treat-
ment does not eliminate the risk of progression to active
TB, completion of a proven LTBI treatment regimen (e.g.,
6 or 9 months of daily isoniazid, 4 months of daily rifam-
pin, 12 doses of weekly isoniazid and rifapentine) dramat-
ically decreases that risk [4]. The US’ strategic plan to
eliminate domestic TB includes risk-targeted identification
and treatment of people with LTBI [5]. This strategy is
supported by the US Preventive Services Task Force’s
(USPSTF) recent “Grade B” rating for LTBI testing in
high-risk populations, which indicates to primary care
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providers that targeted LTBI testing and treatment afford
moderate health benefit with little risk [6, 7].
Public health agencies have traditionally provided most
TB control and prevention services in the US [8–11]. How-
ever, the USPSTF’s rating and current policy will likely drive
increased involvement by private sector providers as health
insurers are now required to cover TB/LTBI testing in
high-risk populations with no patient cost sharing [12]. At
the same time, the uninsured rate in the US is decreasing
[13] and health insurance coverage is associated with in-
creased use of primary and other private sector health care
[14]. These shifts present an opportunity to coordinate
public/private approaches to TB prevention. Factors associ-
ated with LTBI treatment completion are seldom studied
outside of public health settings [15, 16]. Differences in pa-
tient risks, provider and patient incentives, and care pro-
cesses in the private sector suggest a need for more
information about the factors associated with treatment
completion in this increasingly important arena.
We used a national sample of commercial claims data
to examine private sector LTBI treatment across the US
as a step toward filling this gap. Insurance claims offer a
window into private healthcare practice patterns [17].
We aimed to use these data to identify factors associated
with the completion of daily dose isoniazid LTBI treat-
ment in the private sector setting.
Methods
Data source and analytic sample
We analyzed de-identified medical and pharmacy claims
from Optum Clinformatics® Data Mart (formerly called
the National Research Database) which includes claims
for approximately 30.6 million commercially insured indi-
viduals – about 19% of the commercially insured US
population [18]. We analyzed data for a randomly selected
sample of 4 million people who were ages 0 to 64 years.
Additional details about this sample are described else-
where [19]. We used a claims-based algorithm to identify
individual 6 to 9 month daily dose isoniazid courses of
treatment for LTBI [19], which have been the most com-
monly used LTBI treatment regimens [20]. We examined
treatment initiated between July 2011 and March 2014. In
addition to requiring that data be available to determine if
treatment was completed (as specified in the algorithm)
[19] we required non-missing socio-demographic variables
(i.e., the percent of foreign-born in county, patient loca-
tion category, percent of households in county living
under the federal poverty level (FPL), and state TB rate).
Measures
Outcome variable
The outcome of interest was completion of daily isoniazid
treatment for LTBI [21]. Patients may be prescribed a 6 or
9-month isoniazid regimen [4]. While our data do not
indicate whether the 6 or 9-month regimen was prescribed,
we could determine how many doses of isoniazid were dis-
pensed. Thus, we grouped isoniazid treatments into three
mutually exclusive ordinal categories: 1) non-completion
(< 180 doses received within 9-months), 2) completion of
the 6-month regimen but not the 9-month regimen (180 to
269 doses received within 9-months), or 3) completion of
the 9-month regimen (≥ 270 doses received within
12-months) [20]. These increasing levels of completion are
important because, while isoniazid treatment completion at
any duration does not necessarily imply LTBI cure, the risk
of progression to active TB decreases as the duration of iso-
niazid treatment increases [22].
Explanatory variables
Explanatory variables were constructed from the medical
and pharmacy claims data (see Additional file 1 for details).
Socio-demographic variables included sex, age, census re-
gion, and a patient location variable based on the National
Center for Health Statistics urban-rural classification [23].
The percentage of households living under the federal pov-
erty level in a patient’s county served as a proxy for house-
hold income [24]. Additional variables included insurance
type (health maintenance organization [HMO], point of
service [POS], or preferred provider organization [PPO]),
prescription size (the supply of isoniazid received when the
first prescription was filled; < 2 months or ≥ 2 months),
year, and the type of LTBI diagnostic test received in the
6 months before treatment initiation. Non-clinical variables
related to risk of LTBI or progression to active TB were in-
cluded, such as the state TB rate. While country of birth
was unavailable, we included prevalence of foreign-born in-
dividuals in the patient’s county as a proxy [25, 26]. Clinical
risk factors included diabetes, tobacco use, HIV, immuno-
suppressive medication use, contact with or exposure to
TB, and a history of or late effects of TB [27]. A simple
count of each patient’s clinical risk factors represented cu-
mulative risk (i.e., 0, 1, or > 1 risk factor).
Statistical analyses
We calculated the proportion of individuals in each of
three categories of treatment completion (i.e., < 6 months,
6 to < 9 months, ≥9 months) and examined the bivariate
relationships between the explanatory variables and com-
pletion using Kruskal-Wallis tests and Spearman correla-
tions. We explored the adjusted association between these
variables and treatment completion category using multi-
variable generalized ordered logit models. Variables meet-
ing the parallel-lines assumption were constrained to have
equal effects; the odds ratios for non-completion versus
completing ≥6 months of treatment and those for com-
pleting < 9 months of treatment versus ≥9 months of
treatment were the same. Variables violating the assump-
tion were not constrained and consequently have different
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odds ratios for completion category comparisons [28]. We
ran two multivariable generalized ordered logit models. In
Model 1 we examined the relationship between completion
and cumulative risk. Model 2 explored the relationship be-
tween completion and individual clinical risk factors.
We also ran a multivariable logit model with completion
of ≥6 months of treatment as the outcome measure and
all predictors from the more detailed Model 2 as explana-
tory variables. This logit model was used to examine the
reduction of variance in the treatment completion variable
attributable to each predictor, which provided insight into
the importance of the variables with respect to model pre-
dictions of completing ≥6 months of treatment [29, 30].
We conducted two sets of post hoc analyses. First, in
order to assess the robustness of our findings we conducted
sensitivity analyses using variations on our treatment com-
pletion outcomes measure. We ran four multivariable logis-
tic regression models to explore characteristics associated
with completion of ≥5 months of treatment and compare
the results to the characteristics associated with ≥6 months
of treatment in Models 1 and 2. Four models were used be-
cause we had two sets of explanatory variables (see descrip-
tions of Models 1 and 2 above), and we defined completion
two ways: 1) 150 doses in 9 months, and 2) 150 doses in
8 months. We explored the data using two definitions be-
cause we identified no previous studies or clinical practice
guidelines defining a time period in which 150 doses
(5 months) of isoniazid would be considered completed
treatment.
Second, we explored our findings related to the LTBI
testing variable. We ran a frequency distribution which
contained additional details about the LTBI tests re-
ceived. Additionally, to clarify differences between the
results in our bivariate and multivariable analyses, we
conducted post hoc bivariate analyses exploring the rela-
tionship between the explanatory variables and the type
of LTBI diagnostic test using chi square tests for cat-
egorical variables and ANOVAs for continuous variables.
We used Stata 14.2 for most statistical testing [31] but
used IBM SPSS Modeler 17 to complete the importance
analysis [32]. All statistical testing was two-sided, and sig-
nificance was tested at p < .05.
Results
Two (0.2%) of 1074 individuals identified with the
algorithm as having initiated isoniazid LTBI treat-
ment were excluded due to missing geographic vari-
ables. Of the remaining 1072 almost half (46.2%)
completed ≥6 months of treatment. The balance
(53.8%) initiated but did not complete the minimum
6-months course. Roughly equal proportions com-
pleted ≥6 but < 9 months treatment or ≥ 9 months
(23.6 and 22.6% of all patients, respectively; Table 1).
Tables 2 and 3 describe relationships between the ex-
planatory variables and the likelihood of treatment com-
pletion from bivariate analyses and multivariable models,
respectively. Significant unadjusted non-clinical factors as-
sociated with completion included younger age, PPO in-
surance, larger prescription size, and residing in a county
with < 15% of households below FPL. Similarly, in the
multivariable models younger people (ages 0 to 14 years)
had higher adjusted odds of treatment completion than
older people. Compared to people in large central metro-
politan counties, those in large fringe metropolitan coun-
ties had lower adjusted odds of completing ≥6 months of
treatment, although this association was not seen with
completing ≥9 months of treatment. Residing in a county
with ≥15% of households below FPL was significantly as-
sociated with lower adjusted odds of completion. Detailed
adjusted odds ratios for the associations described above
are found in Table 3.
Insurance type and prescription size were also signifi-
cantly associated with completion. The adjusted odds of a
PPO-insured patient completing ≥6 months of treatment
were 1.8 to 1.9 times that of an HMO-insured patient, and
the odds of a PPO-insured patient completing ≥9 months
were 2.8 to 2.9 times that of an HMO-insured patient. Lar-
ger prescription size was associated with higher adjusted
odds of completing ≥9 months of treatment, although this
association was not seen for completing ≥6 months of
treatment.
IGRA testing, HIV, and immunosuppressive medica-
tion use each had statistically significant bivariate associ-
ations with treatment completion. In the multivariable
model, people with HIV had an adjusted 2.5 times
greater odds of an increased level of completion relative
to those without. Additionally, both unadjusted and ad-
justed likelihood of completion was significantly associ-
ated with cumulative clinical risk. Compared to people
with no clinical risk factors, those with one risk factor
had 1.5 times greater adjusted odds and those with more
than one risk factor had 1.8 times greater adjusted odds
of an increased level of treatment completion. The im-
portance analysis indicated that the most important vari-
able in predicting treatment of ≥6 months of treatment was
patient location, followed closely by immunosuppressive
Table 1 Completion of daily-dose isoniazid treatment for latent
tuberculosis infection. N = 1072




Less than 6 months (Incomplete
treatment)
577 53.82 50.82–56.79
At least 6 months 495 46.18 43.20–49.17
≥6 months but < 9 months 253 23.60 21.15–26.24
≥9 months 242 22.57 20.17–25.18
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Table 2 Frequency distribution of patient characteristic variables for people initiating daily-dose isoniazid treatment and the
proportion of people completing treatment by each characteristic. Treatment completion was categorized as 1) less than 6 months
completed, 2) at least 6 months but less than 9 months completed, and 3) 9 or more months completed
Distribution % Achieving Each Level of Isoniazid Treatment
Completion
% Completing ≥6 Mo.

























Sex Female 575 53.6% 55.8% 22.1% 22.1% 0.232 44.2% 0.158
Male 497 46.4% 51.5% 25.4% 23.1% 48.5%
Age Group 0–14 105 9.8% 43.8% 24.8% 31.4% 0.019 56.2% 0.064
15–29 291 27.1% 58.8% 23.4% 17.9% 41.2%
30–44 321 29.9% 53.9% 25.2% 20.9% 46.1%
45–64 355 33.1% 52.7% 22.0% 25.3% 47.3%
Census Region Northeast 352 32.8% 54.8% 20.5% 24.7% 0.148 45.2% 0.151
Midwest 174 16.2% 52.3% 25.3% 22.4% 47.7%
South 148 13.8% 61.5% 22.3% 16.2% 38.5%









413 38.5% 57.6% 19.6% 22.8% 42.4%
Any smaller
county
175 16.3% 55.4% 24.6% 20.0% 44.6%
% of Households Under
FPL in County
< 15% 596 55.6% 51.7% 22.8% 25.5% 0.035 48.3% 0.115
≥15% 476 44.4% 56.5% 24.6% 18.9% 43.5%
Insurance Type HMO 188 17.5% 62.2% 21.3% 16.5% 0.005 37.8% 0.022
POS 742 69.2% 52.8% 25.1% 22.1% 47.2%
PPO 142 13.2% 47.9% 19.0% 33.1% 52.1%
INH Days Supply




991 92.4% 54.5% 24.1% 21.4% 0.020 45.5% 0.126
≥2 month
supply
81 7.6% 45.7% 17.3% 37.0% 54.3%
Year INH Regimen
Started
2011 Q3–4 230 21.5% 58.3% 23.0% 18.7% 0.308 41.7% 0.298
2012 Q1–4 450 42.0% 54.4% 21.8% 23.8% 45.6%
2013 Q1–4 346 32.3% 50.3% 26.3% 23.4% 49.7%
2014 Q1 46 4.3% 52.2% 23.9% 23.9% 47.8%
State TB Rate – 3.85 3.84 3.81 0.846 3.83 0.864
LTBI Diagnostic Test TST 441 41.1% 53.5% 22.9% 23.6% < 0.001 46.5% 0.005
IGRA 219 20.4% 45.2% 23.7% 31.1% 54.8%
Unknown/
Other
412 38.4% 58.7% 24.3% 17.0% 41.3%
Percent Foreign Born in County – 19.96 20.24 20.97 0.403 20.60 0.516
Count of Clinical Risk
Factors
None 662 61.8% 58.0% 22.2% 19.8% 0.011 42.0% 0.002
1 304 28.4% 47.7% 27.0% 25.3% 52.3%
2 or more 106 9.9% 45.3% 22.6% 32.1% 54.7%
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medication use (Fig. 1; see Additional file 2 for logistic re-
gression model results).
The results of the sensitivity models examining
≥5 months of treatment were quite similar to the
primary analyses wherein completion was defined as
≥6 months of treatment (see Additional file 3 for de-
tailed sensitivity model results). All findings were
directionally identical and odds ratios were of similar
magnitude. While most variables were consistent in
terms of statistical significance, there were two ex-
ceptions. Some age group and insurance type cat-
egories that were significant in the primary analyses
were not significant in the sensitivity analyses. How-
ever, the p-values for these categories approached
significance, ranging from p = 0.052 to p = 0.072.
Based on these results we concluded that the results
of our primary analyses were robust to variations in
the definition of treatment completion.
Additional post hoc analyses indicated that 34.9% of
the individuals initiating LTBI treatment had no proced-
ure or diagnostic code in the medical claims data specif-
ically indicating that an LTBI test occurred, although the
majority of these individuals had a diagnosis of LTBI
(Table 4). We also identified significant associations be-
tween LTBI diagnostic test type and our model’s ex-
planatory variables (Table 5). Diagnostic test type was
significantly associated with age, region, patient location,
insurance plan type, year, clinical risk factor count, his-
tory of or late effects of TB, HIV, diabetes, tobacco use,
and immunosuppressive medication use.
Discussion
We used commercial insurance claims data to identify
important individual, clinical, and system factors associ-
ated with the completion of LTBI treatment with isonia-
zid. Most striking were significant associations between
Table 2 Frequency distribution of patient characteristic variables for people initiating daily-dose isoniazid treatment and the
proportion of people completing treatment by each characteristic. Treatment completion was categorized as 1) less than 6 months
completed, 2) at least 6 months but less than 9 months completed, and 3) 9 or more months completed (Continued)
Distribution % Achieving Each Level of Isoniazid Treatment
Completion
% Completing ≥6 Mo.





























923 86.1% 54.3% 23.8% 21.9% 0.296 45.7% 0.457
Had
diagnosis
149 13.9% 51.0% 22.2% 26.9% 49.0%




1027 95.8% 54.2% 23.1% 22.7% 0.426 45.8% 0.197
Had
diagnosis
45 4.2% 44.4% 35.6% 20.0% 55.6%
HIV Positive No
diagnosis
1030 96.1% 54.7% 23.4% 21.9% 0.004 45.3% 0.007
Had
diagnosis
42 3.9% 33.3% 28.6% 38.1% 66.7%
Diabetes No
diagnosis
999 93.2% 54.5% 23.5% 22.0% 0.085 45.6% 0.126
Had
diagnosis













948 88.4% 55.1% 23.0% 21.9% 0.030 44.9% 0.025
Had
medication
124 11.6% 44.4% 28.2% 27.4% 55.6%
aBased on an ICD-9-CM code of V01.1. Abbreviations: INH isoniazid, FPL federal poverty level, TB tuberculosis, TST tuberculin skin test, IGRA interferon-gamma
release assays, LTBI latent tuberculosis infection, HMO health maintenance organization, POS point of service, PPO preferred provider organization
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Table 3 Results of two multivariable generalized ordered logit modelsa with partial proportional odds which examine associations
between patient characteristics and the completionb of daily-dose isoniazid treatment for latent tuberculosis infection (N = 1072)
Model 1: Includes Count of Clinical Risk Factors Model 2: Includes Specific Clinical Risk Factors
Independent Variables Adjusted Odds Ratio 95% Confidence
Interval
p-value Adjusted Odds Ratio 95% Confidence
Interval
p-value
Sex Female 1.000 1.000
Male 1.085 0.855 1.378 0.501 1.045 0.818 1.335 0.724
Age Group 0–14 1.000 1.000
15–29 0.547 0.351 0.854 0.008 0.552 0.353 0.863 0.009
30–44 0.597 0.385 0.925 0.021 0.599 0.386 0.930 0.022
45–64 0.584 0.370 0.920 0.020 0.574 0.362 0.909 0.018
Census Region Northeast 1.000 1.000
Midwest 0.934 0.588 1.483 0.772 0.933 0.587 1.484 0.771
South 0.716 0.466 1.102 0.129 0.692 0.449 1.069 0.097
West 0.989 0.676 1.448 0.956 0.967 0.661 1.416 0.864
Patient Location Neither regimen completed vs. ≥6 months completed (completed 6 or 9 month regimen)
Large central metro county 1.000 1.000
Large fringe metro county 0.600 0.414 0.868 0.007 0.592 0.408 0.858 0.006
Any smaller county 0.767 0.495 1.189 0.235 0.776 0.500 1.203 0.256
< 9 months completed (neither regimen or 6 month regimen completed) vs. ≥9 months completed
Large central metro county 1.000 1.000
Large fringe metro county 0.800 0.537 1.193 0.275 0.791 0.530 1.182 0.253




< 15% 1.000 1.000
≥15% 0.628 0.469 0.841 0.002 0.609 0.454 0.817 0.001
Insurance Type Neither regimen completed vs. ≥6 months completed (completed 6 or 9 month regimen)
HMO 1.000 1.000
POS 1.434 0.981 2.097 0.063 1.513 1.032 2.218 0.034
PPO 1.817 1.147 2.878 0.011 1.864 1.174 2.961 0.008
< 9 months completed (neither regimen or 6 month regimen completed) vs. ≥9 months completed
HMO 1.000 1.000
POS 1.434 0.981 2.097 0.063 1.513 1.032 2.218 0.034
PPO 2.840 1.745 4.622 < 0.001 2.921 1.789 4.767 < 0.001
Prescription Size Neither regimen completed vs. ≥6 months completed (completed 6 or 9 month regimen)
< 2 month supply 1.000 1.000
≥2 month supply 1.419 0.884 2.278 0.148 1.395 0.867 2.245 0.170
< 9 months completed (neither regimen or 6 month regimen completed) vs. ≥9 months completed
< 2 month supply 1.000 1.000
≥2 month supply 2.268 1.383 3.720 0.001 2.233 1.359 3.670 0.002
Year INH Regimen
Started
2011 Q3–4 1.000 1.000
2012 Q1–4 1.109 0.802 1.532 0.531 1.104 0.798 1.526 0.551
2013 Q1–4 1.268 0.906 1.774 0.167 1.261 0.901 1.766 0.177
2014 Q1 1.333 0.720 2.468 0.361 1.333 0.718 2.473 0.363




IGRA 1.255 0.897 1.757 0.185 1.171 0.829 1.653 0.371
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a patient’s insurance plan type and treatment comple-
tion, suggesting that benefit design is a potential means
to modify patient behaviors and ultimately TB risk.
HMO plans, the most tightly managed insurance design,
were associated with the lowest likelihood of completion;
PPO plans, the least restrictive plans, were associated
with the highest. Completion differences may be due to
differences in access or cost sharing, as such health plan
characteristics are associated with continued adherence
to other types of medications [32].
The lower completion rates for HMO-insured individ-
uals suggest a need for HMOs to monitor and conduct
quality improvement initiatives that improve enrollees’
LTBI treatment completion rates. Such activities would
not be unusual – HMOs in most states are required to
operate quality assurance programs that involve moni-
toring and conducting activities to improve care pro-
cesses and clinical outcomes, such as improving
medication adherence rates [33]. As private sector LTBI
treatment becomes more common, the National Com-
mittee for Quality Assurance (NCQA) should consider
incorporating an LTBI treatment completion measure
into its standard set of quality performance measures
(Healthcare Effectiveness Data and Information Set
[HEDIS]) [34]. Health plans’ quality improvement activ-
ities often focus on improving HEDIS rates, as many
states consider quality assurance requirements met if
plans maintain NCQA accreditation [33] and plans are
required to calculate HEDIS measures to attain and
maintain accreditation [35].
Pharmacy benefit design and prescribing offer similar
opportunities to decrease TB risk through improved
treatment completion. Individuals filling larger prescrip-
tions (≥ 2 months supply) had greater odds of complet-
ing a 9-month regimen. Although we cannot be certain
given data limitations, completion of the longer regimen
may be due to the use of mail order pharmacies with
automatic refill programs. Many insurers disallow com-
munity pharmacies from providing a > 1-month supply
of a medication. However, enrollees may be able to use
mail order pharmacies to receive up to a 90-day supply
[36], and mail order pharmacies are more likely to have
automatic refill programs [37]. These programs address
patient passivity and transportation barriers by mailing
prescription refills at regular intervals. Thus, encour-
aging patients to fill larger prescriptions and use
Table 3 Results of two multivariable generalized ordered logit modelsa with partial proportional odds which examine associations
between patient characteristics and the completionb of daily-dose isoniazid treatment for latent tuberculosis infection (N = 1072)
(Continued)
Model 1: Includes Count of Clinical Risk Factors Model 2: Includes Specific Clinical Risk Factors
Independent Variables Adjusted Odds Ratio 95% Confidence
Interval
p-value Adjusted Odds Ratio 95% Confidence
Interval
p-value
Unknown/Other 0.813 0.616 1.071 0.141 0.812 0.615 1.071 0.141




1 1.522 1.158 2.001 0.003 na na na na
2 or more 1.816 1.188 2.778 0.006 na na na na
Diagnosis of
Contact w/ TB
No diagnosis na na na na 1.000
Had diagnosis na na na na 1.289 0.916 1.814 0.145
History of TB/Late
Effects
No diagnosis na na na na 1.000
Had diagnosis na na na na 1.152 0.655 2.027 0.624
HIV Positive No diagnosis na na na na 1.000
Had diagnosis na na na na 2.578 1.377 4.827 0.003
Diabetes No diagnosis or medication na na na na 1.000
Had diagnosis or medication na na na na 1.458 0.902 2.355 0.124
Tobacco No diagnosis or medication na na na na 1.000




No medication na na na na 1.000
Had medication na na na na 1.470 0.997 2.167 0.052
aConstraints for parallel lines were applied to all independent variables except patient location, insurance type, and isoniazid days supply received
bFor both models, isoniazid treatment completion was categorized as 1) less than 6 months completed, 2) at least 6 months but less than 9 months completed,
and 3) 9 or more months completed
Abbreviations: INH isoniazid, FPL federal poverty level, TB tuberculosis, TST tuberculin skin test, IGRA interferon-gamma release assays, LTBI latent tuberculosis
infection, HMO health maintenance organization, POS point of service, PPO preferred provider organization
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automated mail order programs may increase 9-month
isoniazid completion rates so long as appropriate clinical
monitoring to avoid hepatotoxicity and other complica-
tions is ensured [21].
Our analysis suggests that private sector providers are
likely sensitive to and communicating the importance of
treatment completion for LTBI patients at high risk of ac-
tive TB. Patients with serious known risk factors such as
HIV and immunosuppressive medication use [27] are more
likely to complete treatment than others, and immunosup-
pressive medication use is of particular importance in pre-
dicting adherence. Correspondingly, completion was
increasingly likely as the total number of clinical risk factors
increased. Nevertheless, there are opportunities to improve
completion in high-risk private sector patients, as nearly
half of those with one clinical risk factor and 45.3% of those
with > 1 risk factor did not complete at least 6 months of
LTBI treatment. As shorter-course regimens (e.g., 3 months
of weekly isoniazid and rifapentine; 4 months of daily ri-
fampin) typically have higher completion rates [38, 39], the
use of these regimens would likely increase treatment com-
pletion rates. We also found that TST is much more likely
to be used among young children than IGRA. This is con-
sistent with the CDC guidelines [40] and suggests that
Fig. 1 Bar chart depicting the importance of variables in predicting completion of ≥6 months of isoniazid treatment for latent tuberculosis
infection (LTBI). Longer bars represent greater importance
Table 4 Frequency distribution of evidence of latent tuberculosis infection (LTBI) testing occurring in the 6 months prior to LTBI






Detailed Categorization N % 95%
Confidence
Interval
TST 441 41.1% 38.2% 41.1% TST procedure code only, or TST code temporally first 441 41.1% 38.2% 44.1%
IGRA 219 20.4% 18.1% 23.0% IGRA procedure code only, or IGRA code temporally first 219 20.4% 18.1% 23.0%
Other/Unknown 412 38.4% 35.6% 41.4% IGRA & TST procedure codes present on same day 2 0.2% 0.0% 0.7%
Other test for MTB occurred based on procedure code (no TST
or IGRA code)
5 0.5% 0.2% 1.1%
No procedure code provided information about testing, but a
diagnosis code indicated that screening occurred
31 2.9% 2.0% 4.1%
No procedure code or diagnosis code regarding testing was
present, but an LTBI diagnosis code was present
261 24.4% 21.9% 27.0%
Neither LTBI testing procedure nor diagnosis information
regarding LTBI was present
113 10.5% 8.8% 12.3%
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Table 5 Bivariate associations between Mycobacterium tuberculosis test type and other patient characteristics. Includes people
initiating daily-dose isoniazid treatment (N = 1072)









Sex Female 42.1% 19.8% 38.1% 0.767
Male 40.0% 21.1% 38.8%
Age Group 0–14 75.2% 8.6% 16.1% < 0.001
15–29 51.5% 11.0% 37.5%
30–44 36.1% 20.9% 43.0%
45–64 27.0% 31.3% 41.7%
Census Region Northeast 46.6% 12.8% 40.6% 0.001
Midwest 36.8% 21.3% 41.9%
South 41.9% 21.6% 36.5%
West 37.9% 26.4% 35.7%
Patient Location Large central metro
county




Any smaller county 34.3% 20.0% 45.7%
% of Households Under FPL in
County
< 15% 41.9% 20.8% 37.3% 0.672
≥15% 40.1% 20.0% 39.9%
Insurance Type HMO 38.8% 13.3% 47.9% 0.015
POS 41.1% 22.5% 36.4%
PPO 44.4% 19.0% 36.6%
Prescription Size < 2 month supply 41.5% 20.0% 38.5% 0.428
≥2 month supply 37.0% 25.9% 37.0%
Year INH Regimen Started 2011 Q3–4 49.1% 23.2% 38.7% 0.001
2012 Q1–4 36.2% 21.8% 42.0%
2013 Q1–4 40.5% 24.9% 34.7%
2014 Q1 54.4% 15.2% 30.4%
State TB Rate 3.9 3.9 3.8 0.363
Percent Foreign Born in County 21.1 20.5 19.2 0.058
Count of Clinical Risk Factors None 46.8% 14.5% 38.7% < 0.001
1 36.8% 26.0% 37.2%
2 or more 17.9% 41.5% 40.6%
Diagnosis of Contact w/ TB No diagnosis 39.8% 20.6% 39.6% 0.058
Had diagnosis 49.7% 19.5% 30.9%
History of TB/Late Effects No diagnosis 42.0% 20.2% 37.9% 0.031
Had diagnosis 22.2% 36.7% 51.1%
HIV No diagnosis 42.4% 19.0% 36.5% < 0.001
Had diagnosis 9.5% 54.8% 35.7%
Diabetes No diagnosis or
medication
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private providers are receiving CDC messaging related to
best practices [21] and are following these practices.
We found that likelihood of completing ≥6 months of
treatment varied by patient location, with individuals in
large fringe metro counties (i.e., suburban counties [23])
having a lower likelihood of completion than those in
large central metro counties (i.e., counties containing an
inner-city [23]). These findings are in contrast to recent
research examining chronic condition medication adher-
ence for rural, suburban, and urban populations in
which no significant differences were found [41]. The
differing LTBI treatment completion rates that we iden-
tified may be due to differences in provider familiarity
with LTBI treatment best practices. Increased provider
awareness of best practices and more years of experience
are associated with increasing provider adherence to best
practices [42, 43]. As TB incidence is much higher in
urban areas than other areas [44], providers in urban
areas have likely had more exposure to patients in need
of LTBI treatment, more exposure to LTBI treatment
guidelines, and a greater awareness of the benefits of
LTBI treatment completion. Claims data do not allow us
to investigate providers’ knowledge of LTBI treatment
best practices, so additional research is warranted to
confirm the cause of the location-related differences.
Even so, given the suburbanization of the US population
[45] and the importance of this variable in identifying
patients likely to complete < 6 months of treatment (see
Fig. 1), our findings identify an important opportunity to
improve LTBI treatment completion rates in patients
treated by private sector providers in suburban areas.
Our finding that IGRA is associated with greater likeli-
hood of treatment completion aligns with anecdotal re-
ports that IGRA testing may yield greater diagnostic
confidence for patients and providers relative to TST.
However, the association is only significant in our un-
adjusted analysis. LTBI test type is also associated with
many other variables, including clinical risk factors, census
region, insurance plan type, and year. After adjusting for
these other variables, there is no significant association be-
tween the receipt of an IGRA and treatment completion.
It is unclear if the use of IGRA facilitates completion or if
IGRA testing is more common in patients with other
characteristics associated with completion.
Claims are a rich source of information about com-
mercial insurance-covered LTBI treatment occurring
across the US, but they have limitations. These data gen-
erally accurately reflect diagnoses and treatment [17],
but accuracy varies with the clarity of coding instruc-
tions and guidelines [46]. There is ambiguity in the diag-
nostic and procedure coding for LTBI. For example,
providers may be using the “contact with or exposure to
tuberculosis” diagnosis code to represent LTBI status ra-
ther than known recent contacts. This might explain in-
consistencies between our findings and prior reports of
better completion rates among TB contacts [47–50].
Conversely, many of our findings regarding LTBI treat-
ment completion are consistent with past research, in-
cluding associations with younger age and higher
income [15, 16]. Additionally, claims data only reflect in-
formation submitted to a third party payer for the pur-
poses of reimbursement [17]. Our finding that LTBI
testing procedure codes were not present in the claims
for over a third of the individuals initiating isoniazid
treatment suggests that some providers are either not
billing for LTBI testing or some patients are receiving
LTBI testing and treatment in different settings. For ex-
ample, a patient might be diagnosed for LTBI in a work-
place, school, or public health department that does not
bill third party payers but subsequently seek treatment
or fill prescriptions in the private sector using insurance
benefits.
Due to limitations of claims data we cannot precisely de-
termine treatment intent or adherence, and conclusions
about provider and patient behavior are based on inference,
not direct report. For instance, it is unclear whether a 6 or
9-month treatment regimen was prescribed for a given pa-
tient. Further, we cannot know if a filled prescription is
Table 5 Bivariate associations between Mycobacterium tuberculosis test type and other patient characteristics. Includes people
initiating daily-dose isoniazid treatment (N = 1072) (Continued)









Tobacco No diagnosis or
medication






No medication 43.8% 16.7% 39.6% < 0.001
Had medication 21.0% 49.2% 29.8%
Abbreviations: INH isoniazid, FPL federal poverty level, TB tuberculosis, LTBI latent tuberculosis infection, HMO health maintenance organization, POS point of
service, PPO preferred provider organization
Stockbridge et al. BMC Public Health  (2018) 18:662 Page 10 of 13
actually consumed, and it is possible that those enrolled in
automatic refill programs may receive refills even if they
have discontinued their treatment. Of course, the uncer-
tainty related to medication consumption applies to all
medication adherence research not involving direct obser-
vation [51]. Fortunately, numerous studies have illustrated
that medication adherence as measured by filled prescrip-
tions is significantly correlated with both medication con-
sumption and drug serum levels [52]. Consequently,
claims-based methods of evaluating medication adherence
are widely used in health services research and quality as-
surance monitoring [53–62].
Data limitations left us unable to identify important TB
risk factors. Patient-level income and country of birth were
unavailable. While 59% of foreign-born people in the US
have private health insurance [13], claims data do not iden-
tify nativity. However, county-level nativity and FPL rates
were included as proxies. Our data also did not detail
treatment-related out-of-pocket costs for isoniazid or office
visits, nor did it provide insight into insurance benefit plan
design or network adequacy. Our analysis examining the
importance of the variables in the model should be inter-
preted with these limitations in mind, as the results only as-
sess the relative importance of variables available within the
administrative claims data. Other, unavailable variables may
be of great importance in predicting treatment completion.
Nevertheless, claims data provide unique opportunities to
better understand LTBI treatment occurring in a setting of
increasing importance for TB prevention in the US.
Conclusions
In the US, patient risks, provider and patient incentives or
barriers, benefits design, and care processes in private
healthcare differ substantially from that of public health
programs. Our findings illustrate that many of these factors
have an impact on LTBI treatment completion. This new
information enables the development of evidence-based
LTBI private sector treatment strategies. Such work is crit-
ical as more private healthcare providers provide LTBI
treatment and as public health authorities consider the op-
portunities and limitations of private healthcare as a partner
to US TB elimination efforts.
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